{"id":"NCT00996580","sponsor":"Teva Women's Health","briefTitle":"A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-09","completion":"2011-09","firstPosted":"2009-10-16","resultsPosted":"2013-06-14","lastUpdate":"2013-06-24"},"enrollment":3597,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pregnancy Prevention"],"interventions":[{"type":"DRUG","name":"DR-103","otherNames":["levonorgestrel/ethinyl estradiol","QuartetteÂ®"]}],"arms":[{"label":"DR-103","type":"EXPERIMENTAL"}],"summary":"This is an open-label, single-treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-103. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.","primaryOutcome":{"measure":"All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","timeFrame":"Day 1 up to year 1","effectByArm":[{"arm":"DR-103: Total","deltaMin":2.82,"sd":null},{"arm":"DR-103: <90 kg Subpopulation","deltaMin":2.46,"sd":null},{"arm":"DR-103: >=90kg Subpopulation","deltaMin":4.54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":94,"countries":["United States"]},"refs":{"pmids":["18672111","24576794"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":3597},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Sinusitis","Nausea"]}}